Journal article
Adjuvant chemotherapy: results and perspectives
Abstract
The overall 5-year survival of surgically resected non-small cell lung cancer (NSCLC) remains less than 50% and is unlikely to improve until there are effective systemic adjuvant therapies. Two studies of the Lung Cancer Study Group (LCSG) have shown a modest impact of adjuvant CAP chemotherapy on disease-free and overall survival. In addition, a Finnish study, which randomized patients with T1-T3, N0 disease to CAP chemotherapy or follow-up, …
Authors
Evans WK
Journal
Lung Cancer, Vol. 12, , pp. s35–s45
Publisher
Elsevier
Publication Date
4 1995
DOI
10.1016/0169-5002(95)00419-2
ISSN
0169-5002